Loading…
Loading…
NURPF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for NURPF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for NURPF and 80,000+ other tickers.
See exactly how NURPF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NURPF and 80,000+ other tickers.
Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of treatments for neurological conditions. Their leading therapeutic compound, trofinetide, is currently undergoing pivotal (Phase III) clinical trials for Rett syndrome, and has also successfully completed Phase II trials targeting Fragile X syndrome. The company is also progressing NNZ-2591, which has finished its initial human trials (Phase I) for a spectrum of rare neurodevelopmental disorders, including Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Willi syndromes. In addition to its drug…
Neuren Pharmaceuticals Limited (NURPF) Q2 2026 Earnings Call Transcript
Hyperion DeFi (NASDAQ: HYPD - Get Free Report) and Neuren Pharmaceuticals (OTCMKTS:NURPF - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk. Valuation and Earnings This table compares Hyperion DeFi
Shares of Neuren Pharmaceuticals Limited (OTCMKTS:NURPF - Get Free Report) were down 13.5% during mid-day trading on Monday. The company traded as low as C$8.53 and last traded at C$8.53. Approximately 2,010 shares were traded during trading, an increase of 104% from the average daily volume of 987 shares. The stock had previously closed
Neuren Pharmaceuticals Limited (NURPF) Discusses Share Buyback Program, Financial Position, and Development Strategy for NNZ-2591 Transcript